Emergent BioSolutions – Revenues fell 20.5% year on year

Emergent BioSolutions Inc. (NYSE:EBS). Last Market Price: 17.94, Change: -0.64, % Change: (-3.44%). Shares trade in the range of 17.75 – 18.84 dollars. It has a market capitalization of 643.16M dollars, making it a Small Cap Stock and has 35.85M outstanding shares. The company has a beta of -0.03, indicating that the stock moves counter to the market. As per the most recent quarterly report, the net income per share (EPS) is 0.94; P/E of 19 indicating, the stock to be overvalued or expected increase in company earnings. It operates in Healthcare sector and belongs to Biotechnology and Drugs industry. Percentage shares held by institutional investors is 60%. The company has a 52 week Price range (low – high) of $ 14.90 – 26.41. Average volumes of shares traded daily are 231,966. Volume traded in the last session was at 251,506, 1.08 times the average volume.

• Reports Q3 (Sep)
• EPS of $0.04 , better than the estimates
• Revenues fell 20.5% year on year to $58.8 million
• Company reaffirms guidance for FY11, sees FY11 revenues of $270-290 million
• States: We manufactured and delivered doses of BioThrax into the SNS, we advanced the development of our infectious disease, oncology and autoimmune programs, and we made progress on Building 55 scale up. In addition, we received an award for the supply of 44.75 million doses of BioThrax to the SNS over the next five years, with a total value of up to 1.25 bln dollars. This clearly underscores the government’s continued commitment to procure BioThrax as a critical medical countermeasure in the US strategic national stockpile

For Q2 (Jun ’11), It had a Net profit margin of 14.21%, an Operating margin of 22.93%. Other Key stats and ratios are : Return on average assets of 10.41%, Return on average equity of 15.59%. The organization has an employee strength of 767

Consensus Recommendation is a Buy.

Estimate for sales for the Year Ending Dec-11 show a mean of 275.87 million dollars, an estimate high of 281.70 million dollars and an estimate low of 270.90 million dollars. A year ago the figures stood at 306.64 million dollars.

Estimate for sales for the Year Ending Dec-12 show a mean of 332.27 million dollars, an estimate high of 345.00 million dollars and an estimate low of 300.38 million dollars. A year ago the figures stood at 313.39 million dollars.

Estimate for EPS for the Year Ending Dec-11 show a mean of 0.56 dollars, an estimate high of 0.59 dollars and an estimate low of 0.53 dollars. A year ago the figures stood at 1.18 dollars.

Estimate for EPS for the Year Ending Dec-12 show a mean of 1.22 dollars, an estimate high of 1.40 dollars and an estimate low of 0.90 dollars. A year ago the figures stood at 1.17 dollars.

Sales for Quarter Ending Sep-11 was estimated at 63.59 million dollars, however the actual sales figure stood at 58.76 million dollars, 4.83 million dollars less than estimates.

Sales for Quarter Ending Jun-11 was estimated at 84.20 million dollars, however the actual sales figure stood at 88.14 million dollars, 3.94 million dollars more than estimates.

Post Written By: Ed Liston Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications. He is widely quoted in various financial publications on the Internet. When Ed is not writing about stocks, investing in stocks, talking about stocks, or otherwise doing something stock related, he likes to go sailing and fishing in his yacht.